About Contact Us Careers

Hypersensitivity Pneumonitis Market Size and Forecast, by Type (Acute, Subacute, Chronic); Treatment (Immunosuppressive, Corticosteroids); End-user (Hospital, Online Pharmacy, Drug Stores, Retail Pharmacy) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5180
  • Published Date: Sep 11, 2025
  • Report Format: PDF, PPT

Hypersensitivity Pneumonitis Market Outlook:

Hypersensitivity Pneumonitis Market size was over USD 1.51 billion in 2025 and is anticipated to cross USD 2.55 billion by 2035, growing at more than 5.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of hypersensitivity pneumonitis is assessed at USD 1.58 billion.

Hypersensitivity Pneumonitis Market O
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The reason behind the growth is impelled by the increasing prevalence of respiratory diseases across the globe. The third biggest cause of mortality is chronic respiratory conditions caused by risk factors including allergens, occupational dangers, and tobacco use. This has increased awareness regarding such conditions among people, leading to better treatment options for hypersensitivity pneumonitis as well. Each year, asthma accounts for more than 160 000 fatalities worldwide.

The development of non-invasive diagnostic procedures are believed to fuel the hypersensitivity pneumonitis market. Imaging and spirometry are non-invasive techniques used in diagnosis and the measurement of the lung's capacity to inhale and exhale air. For instance, HRCT is a noninvasive, precise diagnostic technology used for the proper diagnosis of chronic hypersensitivity pneumonitis.

Key Hypersensitivity Pneumonitis Market Insights Summary:

  • Regional Highlights:

    • The North America hypersensitivity pneumonitis market will dominate more than 37% share by 2035, driven by increasing healthcare spending and improvements in diagnostic and treatment access.

  • Segment Insights:

    • The corticosteroids segment in the hypersensitivity pneumonitis market is forecasted to achieve a 60% share by 2035, driven by benefits provided by corticosteroid treatment in hypersensitivity pneumonitis.
    • The hospital end-user segment in the hypersensitivity pneumonitis market is projected to hold a notable revenue share by 2026-2035, attributed to advancements in diagnostic techniques leading to more hospital visits.

  • Key Growth Trends:

    • Rising Environmental Pollution
    • Growing Geriatric Population

  • Major Challenges:

    • Lack of Awareness
    • Side Effects Associated with Long-Term Treatment

  • Key Players: Pfizer Inc., Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG, Abbott Laboratories Inc., Astra Zeneca Plc.

Global Hypersensitivity Pneumonitis Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 1.51 billion
    • 2026 Market Size: USD 1.58 billion
    • Projected Market Size: USD 2.55 billion by 2035
    • Growth Forecasts: 5.4% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (37% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, Japan, Germany, United Kingdom, France
    • Emerging Countries: China, India, Brazil, Mexico, South Korea

    • Last updated on : 11 September, 2025

Growth Drivers

  • Rising Environmental Pollution – It is expected that rise in the release of harmful gases and chemicals into the air is anticipated to drive the growth of hypersensitivity pneumonitis market. Moreover, hypersensitivity pneumonitis is a long illness that is caused by an allergic reaction to certain substances (allergens) inhaled through the air.
    According to estimates, more than 6 million people die from air pollution-related causes worldwide each year.

  • Growing Geriatric Population- Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease (ILD) that is more common among those older than 65 years owing to weekend immune response, and the rising count of older people across the globe is estimated to drive market growth.
    Lately, the number of individuals over 65 in the globe is more than 8% of the population, and this percentage is anticipated to increase to over 15% of the global population by 2050.

Challenges

  • Lack of Awareness – Owing to the absence of sufficient resources in low economic areas people the knowledge about prescription drugs such as corticosteroids is poor. This may impact the market growth as without proper knowledge this medication can be misused.

  • Risk Associated with Underdiagnosis and Misdiagnosis of Hypersensitivity Pneumonitis

  • Side Effects Associated with Long-Term Treatment

Hypersensitivity Pneumonitis Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

5.4%

Base Year Market Size (2025)

USD 1.51 billion

Forecast Year Market Size (2035)

USD 2.55 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Hypersensitivity Pneumonitis Market Segmentation:

Treatment Segment Analysis

The corticosteroids segment is estimated to account for 60% share of the global hypersensitivity pneumonitis market in the coming years owing to the benefits provided by this treatment. Corticosteroids are considered in patients with severe lung function impairment as both low-dose oral corticosteroids provide adequate initial treatment of acute hypersensitivity pneumonitis.  Corticosteroids improve survival and slow fibrotic progression in a matched cohort and the therapy may accelerate the initial recovery in persons with severe disease. For instance, corticosteroids such as prednisone usually 60 mg orally once a day for 1 to 2 weeks, are prescribed for severe symptoms or significant lung dysfunction.

End-User Segment Analysis

Hypersensitivity pneumonitis market from the hospital segment is set to garner a notable share shortly on account of growing advancements in diagnostic techniques. Hospitals are equipped with advanced tools for diagnosis of various diseases including hypersensitivity pneumonitis. This may lead to more patients visiting hospitals for managing acute to severe cases of hypersensitivity pneumonitis.

Our in-depth analysis of the global market includes the following segments:

  Type
  • Acute
  • Subacute
  • Chronic

  Treatment
  • Immunosuppressive
  • Corticosteroids

  End-User
  • Hospital
  •  Online Pharmacy
  •  Drug Stores
  •  Retail Pharmacy
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Hypersensitivity Pneumonitis Market Regional Analysis:

North American Market Insights

North America industry is predicted to dominate majority revenue share of 37% by 2035 impelled by the increasing spending in healthcare. This would allocate more resources to the healthcare which may improve the diagnostic capabilities and provide access to treatments for people with hypersensitivity pneumonitis.

According to estimates, Healthcare costs in the US are currently rising by over 1% faster than the GDP every year and by 2028 spending on healthcare in the United States will total more than USD 6 trillion.

European Market Insights

The Europe hypersensitivity pneumonitis market is estimated to be the second largest, during the forecast timeframe led by growing healthcare awareness. Various campaigns and awareness programs are being conducted in the region which has led to an increase in public knowledge about the hypersensitivity pneumonitis disease. As a result, more and more people are being diagnosed with the disease.

Hypersensitivity Pneumonitis Market S
Get Strategic Analysis by Region Now: Request Free Sample PDF

Hypersensitivity Pneumonitis Market Players:

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Svizera Healthcare Pvt. Ltd.
    • Sanofi S.A.
    • Novo Nordisk A/S
    • Eli lilly and Company
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Abbott Laboratories Inc.
    • Astra Zeneca Plc.

Recent Developments

  • Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer which is the second most common type of cancer in the world.
  • Sanofi S.A. an innovative global healthcare company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab) a monoclonal antibody used to treat allergic conditions such as, asthma. Further, is the first and only biologic drug authorized for the treatment of moderate-to-severe atopic dermatitis, and the children treated with Dupixent with topical corticosteroids (TCS) reported that they had cleaner skin and considerably less itching.
  • Report ID: 5180
  • Published Date: Sep 11, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of hypersensitivity pneumonitis is assessed at USD 1.58 billion.

The global hypersensitivity pneumonitis market size surpassed USD 1.51 billion in 2025 and is projected to grow at a CAGR of more than 5.4%, reaching USD 2.55 billion revenue by 2035.

The North America hypersensitivity pneumonitis market will dominate more than 37% share by 2035, driven by increasing healthcare spending and improvements in diagnostic and treatment access.

Key players in the market include Pfizer Inc., Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG, Abbott Laboratories Inc., Astra Zeneca Plc.

Hypersensitivity Pneumonitis Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos